"The Lancet" publishes a study that reveals the effectiveness of insulin pumps in glycemia control in people with type 2 diabetes, a pathology that affects more than 300 million people in the world.
According to the World Health Organization (WHO), type 2 diabetes affects more than 300 million people in the world and, of these, about 20 million require insulin supply therapy .The Opt2Misem study, published in the magazine "The Lancet", shows that these patients achieve better glucose control with the use of insulin pumps than with multiple daily injections.Ignacio Conget, of the Diabetes Unit of the Endocrinology and Nutrition Service of the Clinic Hospital of Barcelona and researcher of the IDIBAPS Diabetes Group, is co -author of the article and one of the members of the Directorate Committee of this international multicentric study.
Although the benefits of insulin pump therapy had already been tested in people with type 1 diabetes, this is the largest study to assess the comparative efficacy of insulin pump therapy in relation to multiple daily injections in patients with patients withType 2 diabetes with bad glycemic control.
For this, Minimed insulin bombs of the Medtronic Medical Technology company have been used.Of the nearly 350 patients who participated in the study, those who used insulin pumps achieved an average reduction of 1.1% at the A1C level (glycosylated hemoglobin), compared to the reduction of just 0.4% in those those in those those in those those in those in those in those in those in those in those in those in those thosethat made use of multiple injections (significant reduction of -0.7 % in favor of the use of the pump).
less complications
A1C reduction is crucial for diabetics, since even a slight decrease contributes significantly to the prevention of possible complications.For each 1% reduction in the A1C, the risk of microvascular complications such as blindness, renal failure or nervous damage, can decrease by 40%.
On the other hand, during the study there was no episode of severe hypoglycemia - under blood sugar level - and it was possible to reduce the daily dose of insulin by more than 20%.In addition, between the two groups of patients, there were no differences in weight gain.
Thus, the Opt2Mise study highlights for the first time, in a considerable number of patients, which the use of an insulin pump is an option of effective and safe treatment in those patients with type 2 diabetes who, even using multiple injections ofInsulin per day, they do not have adequate glycemic control.